Log in to search using one of your social media accounts:

 

Vasotec (Enalapril) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Vaseretic (Enalapril Maleate-Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 8, 2017 Category: Drugs & Pharmacology Source Type: news

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1]. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Know When Airway Discomfort is Indicative of Something Serious
Discussion Coughing is a normal response that protects the airway. Typically, when an irritant enters the airway, the body responds by drawing in a quick breath and then closes the glottis as the air is forced out. This increases the pressure in the airways, which helps move the irritant out of the air passages. As the air is forced out past the closed glottis, the recognizable coughing sound is made. A cough that persists for several days or increases in its intensity and frequency can be a sign of a serious condition. (Source: JEMS Patient Care)
Source: JEMS Patient Care - February 26, 2017 Category: Emergency Medicine Authors: Dennis Edgerly, EMT-P Tags: Airway & Respiratory Columns Source Type: news

Enalapril Improves BP in T1DM Patients With Neuropathy Enalapril Improves BP in T1DM Patients With Neuropathy
Bedtime dosing of enalapril can increase blood pressure dipping in patients with type 1 diabetes and cardiovascular autonomic neuropathy (CAN), new research shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

In Heart Failure Patients, Severe Hyperkalemia Less Common with Sacubitril/Valsartan Than Enalapril (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Among patients with heart failure who are taking a mineralocorticoid receptor antagonist (MRA), the risk for severe hyperkalemia is lower … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2016 Category: Primary Care Source Type: news

Epaned (Enalapril Powder for Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2016 Category: Drugs & Pharmacology Source Type: news

Sacubitril plus valsartan reduces early readmission risk in HF
The risk of readmission within 30 days of heart failure hospitalisation is reduced by a quarter for patients receiving sacubitril/valsartan compared with those receiving enalapril, an analysis of PARADIGM-HF trial data shows. (Source: MedWire News)
Source: MedWire News - July 13, 2016 Category: Consumer Health News Tags: Heart failure Source Type: news

Sacubitril/Valsartan Cuts Readmissions After Heart Failure Hospitalization (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Patients taking the heart failure treatment sacubitril/valsartan are less likely than those taking enalapril to be readmitted after an HF hospitalization, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 11, 2016 Category: Primary Care Source Type: news

Thousands of patients to benefit from £3-a-day treatment rolled out in hospitals from next month 
Sacubitril valsartan cuts death rates by a fifth when compared with enalapril – the current ‘gold standard’ heart failure treatment – and will be rolled out to hospitals in the next month. (Source: the Mail online | Health)
Source: the Mail online | Health - April 27, 2016 Category: Consumer Health News Source Type: news

ATMOSPHERE: Aliskiren Not Superior to Enalapril in HFATMOSPHERE: Aliskiren Not Superior to Enalapril in HF
The negative trial came with a regulatory wrinkle, resulting in three responses being published with the study. The deputy editor admits this was "a bit usual," but so were the circumstances. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

ATMOSPHERE and the RAS Blockade Ceiling in Heart FailureATMOSPHERE and the RAS Blockade Ceiling in Heart Failure
Dr Pina interviews Prof McMurray about the trial on aliskiren and enalapril in HF and the perils of retrospective subgroup analyses. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2016 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news

No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
(American College of Cardiology) In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported at the American College of Cardiology's 65th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2016 Category: Global & Universal Source Type: news

Teens and medicines that cause birth defects: Do doctors drop the ball?
My 14-year-old daughter recently started taking isotretinoin, a medication that can help severe acne — and that can cause severe birth defects. I knew that there was a process in place for preventing pregnancy in girls taking it, but I was caught off guard by just how many hoops we had to jump through to get her prescription. There were two pregnancy tests a month apart at the beginning, continued monthly pregnancy tests as well as monthly online questions about contraception and her understanding of the effects of the medicine, and a special ID card that has to be brought to the pharmacy within a very short window a...
Source: New Harvard Health Information - January 19, 2016 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Children's Health Drugs and Supplements Family Planning and Pregnancy Parenting Source Type: news

Kalev’s story: Advances in medical management of pediatric heart failure
In recent years, the Boston Children’s Hospital Heart Failure team has made significant strides in slowing the progress of heart failure in children. In some cases, disease progression has been slowed enough for the patient to be taken off of the heart transplant list for being “too well.” The following is part three of a four-part series featuring Heart Center patients who were once listed for transplant but were removed thanks to successful medical management of his or her heart disease. Searching for answers Thirty weeks into her second pregnancy, Katie Rosenthal just felt like something was wrong. She...
Source: Thrive, Children's Hospital Boston - November 30, 2015 Category: Pediatrics Authors: Erin Horan Tags: Our patients’ stories congenital heart disease Dr. Leslie Smoot Dr. Pedro del Nido Dr. Sitiram Emani Dr. Wayne Tworetsky heart failure heart transplant Heart transplant program Source Type: news

Folic acid, a B vitamin, lowers stroke risk in people with high blood pressure
If you’re among the one in three American adults with high blood pressure, be sure you’re getting plenty of the B vitamin known as folate. Doing so may lower your odds of having a stroke, an often disabling or deadly event linked to high blood pressure, a new study suggests. Folate occurs naturally in many foods, but especially green leafy vegetables, beans, and citrus fruits. Here in the United States, add to the list most grain products, including wheat flour, cornmeal, pasta, and rice. They are fortified with the synthetic version of folate, known as folic acid. That’s not the case in many countries ar...
Source: New Harvard Health Information - March 18, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements Hypertension and Stroke high blood pressure Source Type: news

Folate Supplementation in HTN May Lower Risk for First StrokeFolate Supplementation in HTN May Lower Risk for First Stroke
Investigators from China say it's time to rethink the possible CV benefits of folic-acid supplementation: adding it to enalapril reduced risk of first stroke in hypertensive patients without CHD. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 16, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Folic acid supplementation among adults with hypertension reduces risk of stroke
(The JAMA Network Journals) In a study that included more than 20,000 adults in China with high blood pressure but without a history of stroke or heart attack, the combined use of the hypertension medication enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American College of Cardiology Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2015 Category: Global & Universal Source Type: news

The year in cardiology: heart failure 2014
The year 2014 has become a remarkable year for heart failure.  The most important news was related to the results of PARADIGM, where LCZ696, the first-in-class angiotensin-receptor neprilysin inhibitor, proved to be superior to enalapril in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction (HFrEF). Read more. Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - February 23, 2015 Category: Cardiology Source Type: news

enalapril, Vasotec, Epaned
Title: enalapril, Vasotec, EpanedCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/29/2015 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - January 29, 2015 Category: Cardiology Source Type: news

Heart failure drug could 'cut deaths by a fifth'
Conclusion This was a well conducted study that achieved impressive results. In this 27 month-long randomised controlled trial of 8,442 people with heart failure and an ejection fraction of 40% or less, compared to enalpril, the new drug LCZ696: reduced the risk of death from cardiovascular disease or the risk of hospitalisation for heart failure by 20% reduced the risk of death from cardiovascular disease by 20% reduced the risk of hospitalisation for heart failure by 21% reduced the risk of death from any cause by 16% Marketing authorisation is now required before it can be sold. The developer of the drug, ...
Source: NHS News Feed - September 1, 2014 Category: Consumer Health News Tags: Heart/lungs Source Type: news

3 Questions That Remain After Novartis' Blockbuster Trial Result
The release of PARADIGM-HF trial in the New England Journal of Medicine, with its stunning results for Novartis’ experimental combination drug, is good news for patients with heart failure and their doctors. The trial was ended early because the combination drug, which included sacubitril (an experimental drug) and valsartan (a current therapy), demonstrated superiority over enalapril (another current therapy). The combination drug reduced the risk of death from heart disease by 20%, death from any cause by 16%, and first hospitalization for heart failure by 21%. Moreover, there was no indication of any safety proble...
Source: Forbes.com Healthcare News - August 30, 2014 Category: Pharmaceuticals Authors: Harlan Krumholz Source Type: news

Novel Heart Failure Drug Combo Cuts CV Mortality More Than Enalapril (FREE)
By Joe Elia Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM LCZ696, an experimental compound that inhibits both angiotensin and neprilysin, "may well represent a new threshold" in treating heart failure, according to an editorialist in the New England Journal of Medicine. Neprilysin is an endopeptidase that degrades certain endogenous vasoactive peptides; its inhibition increases … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2014 Category: Primary Care Source Type: news

Epaned (Enalapril Powder for Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 29, 2013 Category: Drugs & Pharmacology Source Type: news

Great CPC: Metformin toxicity
3.5 out of 5 stars Case 23-2013: a 54-Year-old Woman with Abdominal Pain, Vomiting, and Confusion. Kalantar-Zadeh K et al. N Engl J Med 2013 Jul 25;369:374-382. Full Text This is a very instructive case discussion from the Massachusetts General Hospital. A plane was diverted to Boston because one passenger, a 54-year-old woman, developed increasing abdominal pain and vomiting, along with decreasing mental status. After the plane landed, EMS found that here vital signs were fairly unremarkable (HR = 52 bpm). She was not hypoglycemic. Her medical history included type-2 diabetes, hypertension, and chronic renal disease....
Source: The Poison Review - July 26, 2013 Category: Toxicology Authors: Leon Tags: Medical acute pancreatitis anion gap metabolic acidosis case discussion case records of the massachusetts general hospital metformin toxicity Source Type: news

Case report: hearing loss after snorting oxymorphone
2.5 out of 5 stars Oxymorphone Insufflation Associated with Acute Sensorineural Hearing Loss: Case Files of the University of Massachusetts Medical Toxicology Fellowship. Boyle KL, Rosenbaum CD. J Med Toxicol 2013 Jun:9:179-183. No abstract available This case report describes a 37-year-old man who experienced transient partial hearing loss after snorting crushed Opana® (oxymorphone). The case itself isn’t much, but it provides the opportunity for the authors to present a good discussion of drug-induced ototoxicity. Although opiate-associated hearing loss (OAHL) is well described, the authors state that...
Source: The Poison Review - June 18, 2013 Category: Toxicology Authors: Leon Tags: Medical narcotics opana opiates ototoxicity sensorineural hearing loss Source Type: news

Preventing Heart Damage From Chemotherapy: OVERCOME TrialPreventing Heart Damage From Chemotherapy: OVERCOME Trial
A pilot study shows that the combination of enalapril plus carvedilol prevented left ventricular damage in cancer patients undergoing intensive chemotherapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

enalapril and hydrochlorothiazide, Vaseretic
Title: enalapril and hydrochlorothiazide, VasereticCategory: MedicationsCreated: 4/3/1999 4:02:00 PMLast Editorial Review: 3/8/2013 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 8, 2013 Category: Cardiology Source Type: news

Review: Postpartum management of hypertension
Source: BMJ Area: News The British Medical Journal has featured a review on the postpartum management of hypertension. The most common cause of postpartum hypertension is gestational hypertension or pre-eclampsia that persists after delivery.   In terms of medical management, the review states that suggested first line antihypertensive drugs that are safe in breastfeeding mothers include labetalol, nifedipine, and enalapril. (Source: NeLM - Cardiovascular Medicine)
Source: NeLM - Cardiovascular Medicine - February 26, 2013 Category: Cardiology Source Type: news